Quick Answer
GE HealthCare Technologies Inc. reported Research And Development Expense of $1.26 billion for the year ending 2025.
- GE HealthCare Technologies Inc. showed a decrease of -3.9% in Research And Development Expense from 2024 to 2025.
- This data is from GE HealthCare Technologies Inc.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $238.00 million | Q2 2022: $257.00 million | Q3 2022: $260.00 million | Q1 2023: $270.00 million | Q2 2023: $298.00 million | Q3 2023: $322.00 million | Q1 2024: $324.00 million | Q2 2024: $327.00 million | Q3 2024: $316.00 million | Q1 2025: $344.00 million | Q2 2025: $302.00 million | Q3 2025: $292.00 million.
- Over the full 5 years of available data (2021 to 2025), GE HealthCare Technologies Inc.'s Research And Development Expense has grown by 54.4%.
- Historical annual values: Fiscal year 2025: $1.26 billion | Fiscal year 2024: $1.31 billion | Fiscal year 2023: $1.21 billion | Fiscal year 2022: $1.03 billion | Fiscal year 2021: $816.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: